Trastuzumab for early breast cancer raises important issuesBMJ 2005; 331 doi: https://doi.org/10.1136/bmj.331.7523.1023-a (Published 27 October 2005) Cite this as: BMJ 2005;331:1023
- Edward C F Wilson, research associate (email@example.com)
- Health Economics Group, School of Medicine, Health Policy and Practice, University of East Anglia, Norwich NR4 7TJ
EDITOR—The government's recent announcement that all early stage breast cancer patients are tobe tested for HER2 overexpression with a view to receiving trastuzumab (Herceptin) will no doubt be a great relief to both patients and oncologists1.
However, this raises several important issues.
Firstly, the government may be setting a dangerous precedent in effectively promoting off-licence indications …
Log in using your username and password
Log in through your institution
Register for a free trial to thebmj.com to receive unlimited access to all content on thebmj.com for 14 days.
Sign up for a free trial